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Abstract
Objective: To test the hypothesis that a microalbuminuria (MA) threshold can help predict the risk for the development of
diabetic retinopathy (DR) in type 2 diabetes mellitus (T2DM)_ patients.
Design: We conducted a cross-sectional study of 4739 subjects with T2DM and a prospective study of 297 subjects with
T2DM in China respectively.
Methods: Clinical and laboratory data were collected and biologic risk factors associated with any DR were analysed.
Results: In the cross-sectional study, we found that MA was an independent risk factor for DR development; further, when
the patients were divided into MA deciles, odds ratio (ORs) of DR for the patients in the sixth MA decile (10.7 mg/24 h) was
1.579-fold (1.161–2.147) compared to that for patients in the first MA decile. Furthermore, the OR of DR increased with
a gradual increase in MA levels. Similarly, in the prospective study, during a mean follow-up of 4.5 years, we found that 51
patients (29.0%) of the 176 subjects with high MA level (10.7–30 mg/24 h) developed DR, while 17 patients (14.1%) of the
121 subjects with lower MA (,10.7 mg/24 h) developed DR, and the relative risk ratio of the development of DR is 2.13(95%
CI, 1.58–3.62, P,0.001).
Conclusion: These data suggest that an MA threshold can predict the risk for the development of DR in type 2 diabetes
mellitus, although it is still within the traditionally established normal range.
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Introduction
Diabetic retinopathy (DR) is the most common microvascular
complication of diabetes [1] and the leading cause of acquired
blindness among people of working age in the Western world
[2,3]. The burden of DR is increasing with the rising prevalence
of type 2 diabetes mellitus (DM) [4]. Despite major advances in
the treatment of DR, affected subjects must be identified as early
as possible by aggressively targeting the risk factors and by
regular screening the affected individuals since timely interven-
tion reduces DR progression and vision loss [5]. Numerous
studies have shown that the risk factors for DR include HbA1c
level, hypertension, dyslipidemia, duration of diabetes, age of
onset, microalbuminuria (MA), and cigarette smoking
[6,7,8,9,10].
MA seems to reflect a state of pathophysiological vascular
dysfunction that makes an individual susceptible to organ
damage [11]. Persistence of MA in diabetes patients is a risk
marker not only for kidney and cardiac disorders, but also for
severe ocular morbidity [12,13,14]. Numerous studies have
reported that MA might be an independent risk factor for DR
in type 1 and type 2 DM [12,15,16,17]. On the other hand,
Pedro RA reported that MA is a good predictor of DR in type
1 DM patients but not in type 2 DM patients (7). Therefore, we
sought to clarify the role of MA in the development of
retinopathy in Chinese patients with type 2 DM to determine
if a natural MA threshold exists that can help determine the
increased risk of DR, and, if so, to determine the optimal MA
cut-off point for the identification of individuals at risk for DR
development.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36718Materials and Methods
The study was performed according to the principles of the
Declaration of Helsinki and was approved by the local ethics
committee. All study subjects provided informed consent.
A total of 4,739 patients (2,660 men and 2,079 women) were
included in the cross-sectional study and 297 patients (132 men
and 165 women) were recruited for the prospective study. All
subjects were recruited from Shanghai Diabetes Centre at
Shanghai Jiaotong University -Affiliated Sixth People’s Hospital
and Shanghai Ophthalmology Centre at Shanghai Jiaotong
University -Affiliated First People’s Hospital between the years
2005 to 2009. The diagnosis of diabetes mellitus was performed
according to the World Health Organization (WHO) criteria
which had been reported by WHO study group (1999). We
excluded the patients with acute complications of diabetes mellitus,
a history of non-diabetic renal disease, urinary tract infection,
symptoms or history of a heart disease, and acute or severe chronic
liver disease. In the prospective study, the data were collected both
at baseline and at the patients’ last visit assessment.
Demographic and clinical data, including age, sex, duration of
diabetes, weight, height, and medication, were recorded. Fasting
blood samples were collected to determine fasting plasma glucose,
fasting C peptide, HbA1c, serum lipid and lipoprotein, and serum
creatinine levels. Serum concentrations of high-sensitivity C-
reactive protein were measured using a Dade Behring Nephelom-
eter II System (antiserum to human albumin; Siemens Healthcare
Diagnostics). Albumin excretion rate (AER) was determined in 3
consecutive 24-h urine samples by using the Dade Behring
Nephelometer II System, and the estimated glomerular filtration
rate (eGFR) was calculated using the Modification of Diet in Renal
Disease study equation [18]. Retinopathy status was assessed by
fundus photography (TRC-NW100 camera; Nikon, Japan), and all
images were graded by an experienced ophthalmologist. Presence
of retinopathy was scored as nil, simplex, or proliferative.
For normally distributed variables, the data are expressed as
mean 6 SD. For non-normally distributed values, data are
expressed as the geometric mean [95% confidence interval (CI)].
The level of significance was determined using the t test for
Table 1. Clinical characteristics of type 2 diabetes mellitus patients without or with retinopathy.
Variables No DR DR
Case (M/F) 3464 (1984/1480) 1275 (676/599)
Age (years) 58.6613.9 60.6611.2**
Duration of diabetes (years) 6.566.3 10.667.1**
Age of diagnosis 51.6613.4 49.4611.7**
SBP(mmHg) 130617 136619**
DBP(mmHg) 79698 0 610**
Body-mass index(Kg/m2) 24.863.6 24.763.6
Waist circumference(cm) 88.4610.6 88.5610.6
HbA1c(%) 9.062.4 9.262.1**
FPG (mmol/l) 8.162.8 8.362.1
FCP ( ng/ml) 1.961.2 2.061.3
Antidiabetic drugs n(%)
Monotherapy 983 (28.4%) 940 (27.1%)
Two-drug combinations 1604 (46.3%) 563 (44.2%)
$Three-drug combinations 877 (25.3%) 328 (25.7)
Total cholesterol(mmol/l) 4.761.1 4.861.2
Low-density lipoprotein-cholesterol(mmol/l) 3.266.6 3.469.9
Triglyceride(mmol/l) 1.861.8 1.961.4
High density lipoprotein-cholesterol(mmol/l) 1.260.3 1.160.3
Antilipidemic drug
Statins 347 (10%) 130 (10.2%)
Fibrats 102 (2.9%) 40 (3.1%)
Highly sensitive C-reactive protein(mg/l) 1.10 [0.51–2.82] 1.05 [0.44–2.53]
Microalbuminuria (mg/24h) 9.6 [3.3–209.8] 17.2 [4.0–591.8]**
eGFR(mlNmin-1N1.73m2) 108636 105639**
Hypertention(%) 1478 (41.4%) 618(53.2%)**
Anti-hypertention medication
RAS inhibitor (+) 451 (13.0%) 190 (14.9%)
DR(non/NPDR/PDR) 3464/0/0 0/1011/264
Data are expressed as the means 6 SD or the geometric mean [95% confidence interval (CI)].
DR, diabetic retinopathy.
doi:10.1371/journal.pone.0036718.t001
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used for non-normally distributed values.
The relative contribution of covariates to DR risk was analyzed
by logistic regression and stepwise selection of parameters. Odds
ratios (ORs) for individual risk factors were calculated using
logistic regression analyses. In multiple logistic regression analyses,
DR was used as the dependent variable, and different risk factors
which were identified in univariable logistic regression analysis
were used as independent variables. The results are presented as
OR with 95% CI.
All calculations were performed using the statistical package for
social sciences (SPSS) 17.0 software (Los Angeles, CA). All
reported P values were 2-tailed, and a P value of ,0.05 was
considered statistically significant.
Results
Difference in clinical characteristics between patients
with DR and patients without DR
The demographics of the type 2 DM patients are shown in
Table 1. Of the 4,739 DM patients that were recruited for this
study, retinopathy occurred in 1,275 patients (26.9%) and
nephropathy occurred in 1154 patients (24.4%). Retinopathy
occurred in 794 patients (22.1%), with normoalbuminuria, 304
patients (35.6%) with MA, and 117 patients (59.0%) with
macroalbuminuria. In patients with DR and without DR, there
were significant differences in age (60.6611.2 vs. 58.663.9 years,
P,0.01), age of onset of diabetes (49.4611.7 vs. 51.6613.4 years,
P,0.01), duration of diabetes (10.667.1 vs. 6.566.3 years,
P,0.01), systolic blood pressure (SBP) (136619 vs.
130617 mmHg, P,0.001), diastolic blood pressure (8069 vs.
79610 mmHg, P,0.01), MA (17.2 [4.0–591.8] vs. 9.6 [5.87–
21.2] mg/24 h, P,0.01), HbA1c level (9.262.1 vs. 9.062.4 %,
P,0.01), eGFR (105639 vs. 108636 mL?min
21?1.73 m
2,
P,0.01), and the presence of diabetes (41.4% vs. 53.2%,
P,0.01). There is no difference between the two groups in
BMI, WC, FPG, FCP, lipids, and anti-diabetic medication, anti-
hypertension medication.
Table 2. Risk factors according to presence or absence of diabetic retinopathy as evaluated by a logistic regression model in 4,739
diabetes patients.
Variables DR
Odds Ratio(95%CI) p-value b
Age (years) 0.986(0.981–0.992) ,0.001 20.014
Sex 1.11(0.89–1.37) 0.342
Duration of diabetes (years) 1.906(1.084–1.108) ,0.001 0.091
Age of diagnosis 0.98(0.98–1.012) 0.121
SBP(mmHg) 1.013(1.008–1.017) ,0.001 0.012
DBP(mmHg) 0.972(0.961–1.015) 0.462
Body-mass index(Kg/m2) 1.014(0.945–1.042) 0.722
Waist circumference(cm) 0.988(0.980–0.996) 0.003 20.012
HbA1c(%) 1.048(1.015–1.081) 0.004 0.046
Total cholesterol(mmol/l) 1.163(0.92–1.39) 0.332
Low-density lipoprotein-cholesterol(mmol/l) 0.69(0.597–1.194) 0.124
Triglyceride(mmol/l) 0.823(0.756–1.164) 0.132
High density lipoprotein-cholesterol(mmol/l) 0.79(0.52–1.32) 0.273
Highly sensitive C-reactive protein(mg/l) 0.93(0.88–1.02) 0.524
Microalbuminuria(mg/24h) 1.163(1.134–1.193) ,0.001 0.151
eGFR(mlNmin-1N1.73m2) 0.993(0.992–1.012) 0.282
Hypertension (%) 1.05(0.78–1.37) 0.651
Analysis of maximum likelihood estimates and stepwise selection of parameters.
Microalbuminuria were calculated as ranked variables from deciles of microalbuminuria.
DR, diabetic retinopathy.
doi:10.1371/journal.pone.0036718.t002
Table 3. Microalbuminuria Deciles as Risk Factors for diabetic
retinopathy in 4,739 diabetes patients.
Microalbuminuria
Decile (mg/24 h) DR
Odds Ratio(95%CI) P value
,4.36 1 reference –
$4.36 to ,5.63 1.159(0.844–1.593) 0.326
$5.63 to ,6.28 1.025(0.741–1.419) 0.88
$6.28 to ,8.49 1.186(0.863–1.629) 0.293
$8.49 to ,10.72 1.045 (0.723–1.512) 0.841
$10.72 to ,14.41 1.579(1.161–2.147) 0.004
$14.41 to ,21.43 2.053(1.521–2.772) ,0.001
$21.43 to ,43.0267 2.553(1.899–3.432) ,0.001
$43.94 to ,137.52 3.033(2.294–4.232) ,0.001
$137.52 4.899(3.660–6.557) ,0.001
DR, diabetic retinopathy.
doi:10.1371/journal.pone.0036718.t003
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DR
To determine the independent risk factors for DR, we
performed logistic regression analysis. DR was used as the
dependent variable. Different risk factors which were identified
in univariable logistic regression analysis were used as independent
variables. Our results showed that age, diabetes duration, SBP,
waist circumference, HbA1c level, and MA were the 6 in-
dependent risk factors for DR (Table 2).
Further, to stratify the risk for DR, the patients were divided
into MA deciles, with 472–475 patients in each group. The OR of
DR for patients in the sixth MA decile (10.7 mg/24 h) was 1.579-
fold (1.161–2.147) compared to that of patients in the first MA
decile (P=0.004). Furthermore, the OR of DR increased with
a gradual increase in MA, and OR of DR for patients in the tenth
MA decile was 4.899-fold (3.660–6.557) (P,0.001) (Table 3).
A threshold effect for discriminating those with risk of DR
was confirmed by a prospective study
A hundred seventy-six patients with MA 10.7,30 mg/24 h
(group 1) and 121 patients with MA,10.7 mg/24 h (group 2)
were identified for the prospective study with a mean follow-up
period of 4.5 years (range, 3.7–5.1 years). The clinical character-
istics of the patients in the 2 groups are described in Table 4.
Firstly, follow-up revealed that 68 patients (22.9%) developed DR.
Secondly, this study further showed that 51 patients (29.0%) with
higher MA levels (10.7,30 mg/24 h) and 17 patients (14.1%)
with lower MA levels (,10.71 mg/24 h) developed DR, and that
there was a significant difference for prevalence of DR between
the 2 groups (29.0% vs 14.1%, P,0.001). Notably, these results
were largely unaffected by adjustments for age, creatinine
clearance, hypertension, diabetes, and both total and high-density
lipoprotein.
To further clarify the relationship between the development of
DR and MA, development of DR was selected as a dependent
variable, in contrast, MA as well as other clinical parameters was
regarded as the independent variables to build a multiple logistic
regression model. Only variables that significantly (p,0.05)
differed from the developed DR and non-developed DR groups
entered into the multiple logistic regression analysis. We found
that MA$10.7 mg/24 h was the independent factor for the
development of DR (RR 2.13; 95% CI, 1.58–3.62), and the
relationship existed even after the adjustment of other risk factors.
Discussion
Epidemiological studies have shown that DR and nephropathy
are closely associated [19] and that this correlation can be
explained by a common mechanism involving tissue damage by
the factors mentioned above such as HbA1c level, hypertension,
dyslipidemia, duration of diabetes, age of onset, and cigarette
smoking [6,7,8,9,10]. In 2007, the Kidney Disease Outcomes
Quality Initiative (KDOQI) Clinical Practice Guidelines and
Clinical Practice Recommendations for Diabetes and Chronic
Kidney Disease [20,21] stated that, in most patients with diabetes,
chronic kidney disease is attributable to diabetes if MA is present
along with DR, suggesting that DR plays an important role in the
diagnosis of diabetic nephropathy (DN). In contrast, a precise role
for MA in the screening for and monitoring of DR remains to be
determined.
In the present study, we found that in diabetes patients with
normoalbuminuria, microalbuminuria, and macroalbuminuria,
the prevalence of DR was 22.1%, 35.6%, and 59.0%, respectively,
which is similar to that reported in a previous study [22]. Logistic
regression analysis revealed that MA was closely associated with
DR, along with age, duration of diabetes, SBP, WC, and HbA1c,
and these results were consistent with those of other studies
[6,7,8,9,10,19]. Further, when the patients were divided into MA
Table 4. Clinical characteristics of type 2 diabetic patients without retinopathy at baseline in prospective study.
Variables Microalbuminuria, 10.72mg/24h
Microalbuminuria
10.72–30mg/24h
Case (M/F) 121(53/68) 176 (79/97)
Age (years) 57.2613.7 58.5613.3*
Duration of diabetes (years) 6.266.0 6.666.2**
Age of diagnosis 51.2612.7 52.0612.4
SBP(mmHg) 126.6615.6 131.6615.4**
DBP(mmHg) 78.168.9 80.269.3**
Body-mass index(Kg/m2) 24.263.3 25.163.8**
Waist circumference(cm) 86.7610.1 89.1610.5**
HbA1c(%) 8.962.5 9.262.4**
Total cholesterol(mmol/l) 4.761.1 4.761.1
Low-density lipoprotein-cholesterol(mmol/l) 3.261.0 3.161.0
Triglyceride(mmol/l) 1.761.6 2.062.0**
High density lipoprotein-cholesterol(mmol/l) 1.160.3 1.260.3**
Highly sensitive C-reactive protein(mg/l) 0.92 [0.43–2.09] 1.29 [0.57–3.01]**
Microalbuminuria (mg/24h) 6.362.2 17.165.2**
eGFR(mlNmin-1N1.73m2) 110.5634.9 119.6636.0
Hypertention(%) 40 (33.1%) 72(40.9%)**
Developed DR 17(14.0%) 51(28.98%)**
doi:10.1371/journal.pone.0036718.t004
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decile (10.7 mg/24 h) was 1.579-fold (1.161–2.147) compared
with that for the patients in the first MA decile. Furthermore, the
risk of DR increased with albuminuria progression.
The predictive value of a high normal albuminuria for DN in
patients with type 1 and type 2 DM has already been described
[23,24]. Recently, a study reported a 3-fold increased risk for DN
in patients with urinary albumin excretion (UAE) levels above the
median of 5 mg/min, and even higher progression rates for those
with levels above 10 mg/min [25]. As stated above, in the present
study, an MA threshold of 10.7 mg/24 h predicted increased risk
for the development of DR in type 2 DM patients. There are
several plausible explanations for the risk associated with
normoalbuminuria: Caramori ML reported that normoalbumi-
nuria does not imply normal renal function, and that long-
standing normoalbuminuric type 1 DM patients have reduced
GFRs that are associated with more advanced diabetic glomerular
lesions and, probably, increased risk of progression [26]. Similarly,
another study showed a significant association between DR and
preclinical morphologic changes of DN in type 1 DM patients
[27]. A similar situation may also exist in type 2 DM patients. In
addition, we cannot rule out the possibility that conventional
immunoassays routinely used for albuminuria measurement might
underestimate the actual total urinary albumin levels, which
includes immuno-unreactive albuminuria [28]. Indeed, the cut-off
point is a rather arbitrary threshold based on findings from studies
in the 1980s in which the progression rate to overt nephropathy in
patients with values for albuminuria of 30 mg/24 h was about
80% [23].
One strength of our data is that a prospective study was carried
out on the basis of the findings of the cross-sectional study. We
found that the prevalence of DR in the patients with higher MA
($10.7 mg/24 h) was as two times as that in the patients with
lower MA (,10.7 mg/24 h) (29.0% vs 14.1%, P,0.001), and that
there was a significant difference between the 2 groups, suggesting
that a MA threshold of 10.7 mg/24 h could predict the risk for the
development of DR in type 2 DM patients. We consider this
supporting evidence that what we have observed is a true
phenomenon. In this prospective study, several limitations should
be acknowledged such as a small sample size and a short follow-up
time.
It is interesting to note that, apart from its effects on vision, the
presence of DR also signifies an increased risk of life-threatening
systemic vascular complications, including stroke, coronary heart
disease, heart failure, neuropathy, and nephropathy [29,30,31,32].
Therefore, there is a need for redefining MA accordingly, in order
to screen and monitor not only DR but also other microvascular
and macrovascular complications. As reported by Klausen K, very
low levels of MA (UAE level, 4.8 mg/min) are associated with an
increased risk of coronary heart disease and death independent of
renal function, hypertension, and diabetes. Klausen K also
suggested that MA be redefined accordingly and that intervention
studies be performed [14].
In conclusion, an MA threshold can predict the risk for the
development of DR in type 2 diabetes mellitus, although it is still
within the traditionally established normal range.
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